Philippines FDA Clarifies ‘Reliance Pathways’ For Speeding Up Drug Registration
The Philippines regulator has issued more guidance for companies that want to use its registration pathways for products that are already approved in other countries.
You may also be interested in...
The Philippines FDA is looking to leverage the work conducted by “stringent” regulators when it comes to reviewing certain clinical trial applications.
Companies have the opportunity to tell the European Commission what they think about its proposed regulation that would overhaul the rules governing the use of substances of human origin.
Leniolisib has become the first product to be granted accelerated assessment status by the European Medicines Agency this year.